Dimethyl fumarate for multiple sclerosis
- 1 December 2010
- journal article
- research article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 19 (12), 1603-1612
- https://doi.org/10.1517/13543784.2010.534778
Abstract
(2010). Dimethyl fumarate for multiple sclerosis. Expert Opinion on Investigational Drugs: Vol. 19, No. 12, pp. 1603-1612.Keywords
This publication has 24 references indexed in Scilit:
- Vacuolar Leukoencephalopathy with Widespread Astrogliosis in Mice Lacking Transcription Factor Nrf2The American Journal of Pathology, 2007
- German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version)Archives of Dermatological Research, 2007
- Dimethylfumarate inhibits nuclear binding of nuclear factor ?B but not of nuclear factor of activated T cells and CCAAT/enhancer binding protein ? in activated human T cellsBritish Journal of Dermatology, 2007
- NF-κB and the immune responseOncogene, 2006
- Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltrationClinical and Experimental Immunology, 2006
- Dimethylfumarate for psoriasis: more than a dietary curiosityTrends in Molecular Medicine, 2005
- Identification of anti‐inflammatory drugs according to their capacity to suppress type‐1 and type‐2 T cell profilesClinical and Experimental Allergy, 2004
- Pharmacokinetics of oral fumarates in healthy subjectsBritish Journal of Clinical Pharmacology, 2004
- Monomethylfumarate affects polarization of monocyte‐derived dendritic cells resulting in down‐regulated Th1 lymphocyte responsesEuropean Journal of Immunology, 2004
- Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid estersBiopharmaceutics & Drug Disposition, 2003